PARKINSON'S DISEASE

As of October 2015 - States That Have Approved Medical Marijuana for Parkinson’s Disease

Currently, 10 states have approved medical marijuana for the treatment of Parkinson’s disease. These states include Connecticut, Georgia, Illinois, Maine, Massachusetts, New Hampshire, New Mexico, New York, Ohio and Pennsylvania.
A number of other states will consider allowing medical marijuana to be used for the treatment of Parkinson’s disease with the recommendation from a physician. These states include: California (any debilitating illness where the medical use of marijuana has been recommended by a physician), Nevada (other conditions subject to approval), Oregon (other conditions subject to approval), Rhode Island (other conditions subject to approval), and Washington (any “terminal or debilitating condition”).
In Washington D.C., any condition can be approved for medical marijuana as long as a DC-licensed physician recommends the treatment.
In addition, several states have approved medical marijuana specifically to treat “chronic pain,” a symptom that can arise in people with Parkinson’s. These states include: Alaska, Arizona, California, Colorado, Delaware, Hawaii, Maine, Maryland, Michigan, Montana, New Mexico, Ohio, Oregon, Pennsylvania, Rhode Island and Vermont. The states of Nevada, New Hampshire, Ohio and Vermont allow medical marijuana to treat “severe pain.” The states of Minnesota, Ohio, Pennsylvania and Washington have approved cannabis for the treatment of “intractable pain.”
Also, 17 states have approved medical marijuana specifically for the treatment of nausea, which can develop from medications used to treat Parkinson’s. These states include: Alaska, Arizona, California, Colorado, Delaware, Hawaii, Maine, Maryland, Michigan, Montana, Nevada, New Hampshire, New Mexico, Oregon, Rhode Island, Vermont, and Washington.

Source: Medical Marijuana Inc

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.      https://www.ncbi.nlm.nih.gov/pubmed/25237116

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.  https://www.ncbi.nlm.nih.gov/pubmed/24614667

Studies on Cannabis and Parkinson's Disease

Study Name, Description & Year

---

---

Potential Of The Cannabinoid CB(2) Receptor As A Pharmacological Target Against Inflammation In Parkinson's Disease
Animal study (mice) — 2016

ENDOCANNABINOID SYSTEM: A Multi-facet Therapeutic Target
  Review — 2016

Cannabinoid-dopamine Interactions In The Physiology And Physiopathology Of The Basal Ganglia
Review — 2016

Amyloid Proteotoxicity Initiates An Inflammatory Response Blocked By Cannabinoids
Laboratory Study — 2016

Fatty Acid Amide Hydrolase Inhibition For The Symptomatic Relief Of Parkinson's Disease
Animal study (mice) — 2016

Cannabinoid Type 2 (CB2) Receptors Activation Protects Against Oxidative Stress And Neuroinflammation Associated Dopaminergic Neurodegeneration In Rotenone Model Of Parkinson's Disease
Animal study (Wistar rats) — 2016

Promising Cannabinoid-based Therapies For Parkinson’s Disease: Motor Symptoms To Neuroprotection
Review — 2015

Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications
Review — 2015

Cannabinoid Receptors And Endocannabinoids: Role In Neuroinflammatory And Neurodegenerative Disorders
Literature review — 2010

Cannabidiol: A Promising Drug For Neurodegenerative Disorders?
Meta-analysis — 2009

Treatment Of A Hyperkinetic Movement Disorder During Pregnancy With Dronabinol
Human case study — 2009

WIN55,212-2, A Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss In The MPTP Mouse Model Of Parkinson’s Disease
Animal study (mice) — 2009

Cannabinoids And Neuroprotection In Basal Ganglia Disorders
Review — 2007

Survey On Cannabis Use In Parkinson's Disease: Subjective Improvement Of Motor Symptoms
Patients with Parkinson's — 2004

US Patent 6630507: Cannabinoids As Antioxidants And Neuroprotectants
Meta-analysis — 2003

---

View All Conditions

---

View All Cannabis Studies for Symptoms and Conditions


Source: Cannabis Reports

US Patent No 6630507

I am borrowing this picture above that was posted on the internet.  I've noticed that the US Patent # posted on the picture is not the same Patent # I am sharing with you here.  I have not yet researched for the Patent # mentioned in the picture but I do have information below on Patent # 6630507

US Patent 6630507 -

Cannabinoids as antioxidants and neuroprotectants

The US government holds a patent on medical hemp unlike many of us were led to believe.  Many of us were under the impression that it was a major drug company which held the patent.

We confirmed it at the patent office, that the United States Government, who has imprisoned and caused the untimely deaths of many over the issue of marijuana/hemp, holds a patent on medical hemp. They made it illegal for us to study and use one of the most effective medicines on the planet while they took their time getting a patent on it.

The Department of Health and Human Services hold the patent 6630507, Cannabinoids as antioxidants and neuroprotectants, a medical hemp patent.

Below is the text of the patent, US Patent No 6630507,

US Patent Issued on October 7, 2003

Abstract

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.

The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in theatreatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, HIV  and dementia. 

Nonpsychoactive cannabinoids, such as cannabid oil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.

A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula(I) where in the R group is independently selected from the group consisting of H, CH3, and COCH3. ##STR1##

Inventor(s) Hampson, Aidan J.
Axelrod, Julius
Grimaldi, Maurizio

Assignee The United States of America as represented by the Department of Health and Human Services


ApplicationNo. 09/674028 filed on 02/02/2001

Current US Class 514/454 Tricyclo ring system having the hetero ring as one of the cyclos

Field of Search 514/454 Tricyclo ring system having the hetero ring as one of the cyclos

ExaminersPrimary: Weddington, Kevin E.

Attorney, Agent or Firm Klarquist Sparkman, LLP

US Patent References 2304669, 4876276, (3S-4S)-7-hydroxy-Ɗ6 -tetrahydrocannabinols Issued on: 10/24/1989 Inventor: Mechoulam, et al.5227537,   Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol Issued on: 07/13/1993 Inventor: Stoss, et al.5284867, NMDA-blocking pharmaceutical compositions Issued on: 02/08/1994 Inventor: Kloog, et al.5434295, Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds Issued on: 07/18/1995 Inventor: Mechoulam, et al.5462946, Nitroxides as protectors against oxidative stress Issued on: 10/31/1995 Inventor: Mitchell, et al.5512270, Method of inhibiting oxidants using alkylaryl polyether alcohol polymers Issued on: 04/30/1996 Inventor: Ghio, et al.5521215, NMDA-blocking pharmaceuticals Issued on: 05/28/1996 Inventor: Mechoulam, et al.5538993, Certain tetrahydrocannabinol-7-oic acid derivatives Issued on: 07/23/1996 Inventor: Mechoulam, et al.5635530, (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them Issued on: 06/03/1997 Inventor: Mechoulam, et al.5696109, Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease Issued on: 12/09/1997 Inventor: Malfroy-Camine, et al.6410588 Use of cannabinoids as anti-inflammatory agents Issued on: 06/25/2002 Inventor: Feldmann, et al.International classA61K 31/35 (20060101)

Other References

Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.
Mechoulam et al., "A Total Synthesis of d1-Ɗ1 -Tetrahydrocannabinol, the Active Constituent of Hashish1," Journal of the American Chemical Society, 87:14:3273-3275 (1965)
Mechoulam et al., "Chemical Basis of Hashish Activity," Science, 18:611-612 (1970)
Ottersen et al., "The Crystal and Molecular Structure of Cannabidiol," Acta Chem. Scand. B 31, 9:807-812 (1977)
Cunha et al., "Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients1," Pharmacology, 21:175-185 (1980)
Consroe et al., "Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats," Experimental Neurology, Academic Press Inc., 70:626-637 (1980)
Turkanis et al., "Electrophysiologic Properties of the Cannabinoids," J. Clin. Pharmacol., 21:449S-463S (1981)
Carlini et al., "Hypnotic and Antielpileptic Effects of Cannabidiol," J. Clin. Pharmacol., 21:417S-427S (1981)
Karler et al., "The Cannabinoids as Potential Antiepileptics," J. Clin. Pharmacol., 21:437S-448S (1981)
Consroe et al., "Antiepileptic Potential of Cannabidiol Analgos," J. Clin. Pharmacol., 21:428S-436S (1981)
Colasanti et al., "Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol," Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984)
Colasanti et al., "Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol," Exp. Eye Res., Academic Press Inc., 39:251-259 (1984)
Volfe et al., "Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients," Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985)
Agurell et al., "Pharmacokinetics and Metabolism of Ɗ1 -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*," Pharmacological Reviews, 38(1):21-43 (1986)
Karler et al., "Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,"NIDA Res. Monogr., 79:96-107 (1987)
Samara et al., "Pharmacokinetics of Cannabidiol in Dogs," Drug Metabolism and Disposition, 16(3):469-472 (1988)
Choi, "Glutamate Neurotoxicity and Diseases of the Nervous System," Neuron, Cell Press, 1:623-634 (1988)
Eshhar et al., "Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist," European Journal of Pharmacology, 283:19-29 (1995)
Skaper et al., "The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons," Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996)
Alonso et al., "Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules," J. Org. Chem., American Chemical Society, 62(2):417-421 (1997)
Combes et al. "A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation," Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997)
Shohami et al., "Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome," Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997)
Zurier et al., "Dimethylheptyl-THC-11 OIC Acid," Arthritis & Rheumatism, 41(1):163-170 (1998)
Hampson et al., "Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission," Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998)
Hampson et al., "Cannabidiol and (-)Ɗ9 -tetrahydrocannabiono are Neuroprotective Antioxidants," Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998)

Posted by J. Nayer Hardin at 6:11 PM

CANNABINOIDS Slow Cancer Growth

Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects.

 

Cristina Sanchez, a young biologist at Complutense University in Madrid, was studying cell metabolism when she noticed something peculiar. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. But the cancer cells died each time they were exposed to tetrahydrocannabinol (THC), the principal psychoactive ingredient of marijuana.

Instead of gaining insight into how cells function, Sanchez had stumbled upon the anti-cancer properties of THC. In 1998, she reported in a European biochemistry journal that THC “induces apoptosis [cell death] in C6 glioma cells,” an aggressive form of brain cancer. 

Subsequent peer-reviewed studies in several countries would show that THC and other marijuana-derived compounds, known as “cannabinoids,” are effective not only for cancer-symptom management (nausea, pain, loss of appetite, fatigue), they also confer a direct antitumoral effect. 

A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies. The results were published in 2006 in the British Journal of Pharmacology: THC treatment was associated with significantly reduced tumor cell proliferation in every test subject. 

Around the same time, Harvard University scientists reported that THC slows tumor growth in common lung cancer and “significantly reduces the ability of the cancer to spread.” What’s more, like a heat-seeking missile, THC selectively targets and destroys tumor cells while leaving healthy cells unscathed. Conventional chemotherapy drugs, by contrast, are highly toxic; they indiscriminately damage the brain and body.

There is mounting evidence, according to a report in Mini-Reviews in Medicinal Chemistry, that cannabinoids “represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis [the formation of new blood cells that feed a tumor] and the metastatic spreading of cancer cells.”

Dr. Sean McAllister, a scientist at the Pacific Medical Center in San Francisco, has been studying cannabinoid compounds for 10 years in a quest to develop new therapeutic interventions for various cancers. Backed by grants from the National Institute of Health (and with a license from the DEA), McAllister discovered that cannabidiol (CBD), a nonpsychoactive component of the marijuana plant, is a potent inhibitor of breast cancer cell proliferation, metastasis, and tumor growth. 

In 2007, McAllister published a detailed account of how cannabidiol kills breast cancer cells and destroys malignant tumors by switching off expression of the ID-1 gene, a protein that appears to play a major role as a cancer cell conductor. 

The ID-1 gene is active during human embryonic development, after which it turns off and stays off. But in breast cancer and several other types of metastatic cancer, the ID-1 gene becomes active again, causing malignant cells to invade and metastasize. “Dozens of aggressive cancers express this gene,” explains McAllister. He postulates that CBD, by virtue of its ability to silence ID-1 expression, could be a breakthrough anti-cancer medication. 

“Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy,” says McAllister, who is seeking support to conduct clinical trials with the marijuana compound on breast cancer patients.

McAllister’s lab also is analyzing how CBD works in combination with first-line chemotherapy agents. His research shows that cannabidiol, a potent antitumoral compound in its own right, acts synergistically with various anti-cancer pharmaceuticals, enhancing their impact while cutting the toxic dosage necessary for maximum effect. 

Breast cancer cells killed by CBD on right compared to untreated breast cancer cells on left.
(Courtesy Pacific Medical Center)

“Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy.

Investigators at St. George’s University in London observed a similar pattern with THC, which magnified the effectiveness of conventional antileukemia therapies in preclinical studies. THC and cannabidiol both induce apoptosis in leukemic cell lines. 

At the annual summer conference of the International Cannabinoid Research Society, held this year in Freiburg, Germany, 300 scientists from around the world discussed their latest findings, which are pointing the way toward novel treatment strategies for cancer and other degenerative diseases. Italian investigators described CBD as “the most efficacious inducer of apoptosis” in prostate cancer. Ditto for cannabidiol and colon cancer, according to British researchers at Lancaster University. 

Within the medical science community, the discovery that cannabinoids have anti-tumoral properties is increasingly recognized as a seminal advancement in cancer therapeutics.

Source: The Daily Beast